Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET versus ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET versus ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE.
ACTOPLUS MET vs ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Actoplus Met combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, muscle, and liver. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
ACTOPLUS MET (pioglitazone/metformin) is available as tablets of 15 mg/500 mg, 15 mg/850 mg, and 15 mg/1000 mg. The usual starting dose is 15 mg/500 mg twice daily or 15 mg/850 mg once daily, gradually titrated based on glycemic response and tolerability. Maximum recommended dose is 45 mg pioglitazone and 2000 mg metformin per day.
Oral, initial: rosiglitazone 2 mg plus metformin 500 mg twice daily; maximum: rosiglitazone 8 mg plus metformin 2000 mg per day (divided twice daily).
None Documented
None Documented
Pioglitazone: terminal half-life 3–7 hours (parent drug) for elimination, with active metabolites prolonging clinical effects up to 24 hours. Metformin: 6.2 hours (plasma), prolonged to 17.6 hours in renal impairment (e.g., CrCl <60 mL/min).
Metformin: 4-8.7 h (elimination), prolonged in renal impairment; Rosiglitazone: 3-4 h (terminal), slightly longer in hepatic impairment.
Pioglitazone: predominantly hepatic metabolism and biliary excretion of metabolites, with 15–30% recovered in urine (mostly metabolites) and the remainder in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion, with <10% in feces.
Metformin: 90% renal unchanged via tubular secretion; Rosiglitazone: 64% renal (metabolites), 23% fecal. Combined: minimal biliary excretion.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione